HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast CancerDevra J. Olson, Anita Kulukian|Cancer Research Communications|2023Cited by 18